PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Candesartan cilexetil - Migraine (prevention)
PAD Profile : Candesartan cilexetil - Migraine (prevention) Important
Keywords :
migraine prophylaxis, migraine prevention
Brand Names Include :
Amias
Important Information :
Off-label use
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Botulinum toxin type A
- Flunarizine dihydrochloride
- Pizotifen malate
- Erenumab
- Galcanezumab
- Fremanezumab
- Propranolol hydrochloride
- Topiramate
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Rimegepant
- Clonidine hydrochloride
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (Local)
01 February 2026
Committee Recommendations
Date
Committee Name
Narrative
01 March 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends candesartan as a treatment option for migraine prophylaxis.
Note - candesartan is not licensed for this indication (off-label use)
Associated BNF Codes
04. Central Nervous System
04.07.04. Antimigraine drugs